Biomet reported net sales for the second quarter of the 2011 fiscal year at $698.3 million, compared to the net sales of the second quarter of 2010 of $695.6 million, according to a company news release.
Net sales for the American market increased by 2 percent during the second quarter while the Europe net sales decreased by 8 percent and the international sales increased by 12 percent. The company foresees an improving economy, favorable demographics and product innovation to lead to a successful future.
Knee sales increased by 2 percent worldwide, extremity sales by 21 percent and sports medicine sales by 16 percent worldwide. The sales of spine products experienced a 3 percent decrease during the second quarter.
Read the release on Biomet's 2Q FY 2011 financial report.
Read other coverage on Biomet:
- Biomet Completes Enrollment for FDA Trial for PRP Device for Tennis Elbow Treatment
- Biomet Nederland, Small Bone Innovations Sign Distribution Agreement
- Biomet Acquires Massachusetts' Cytosol Laboratories
Net sales for the American market increased by 2 percent during the second quarter while the Europe net sales decreased by 8 percent and the international sales increased by 12 percent. The company foresees an improving economy, favorable demographics and product innovation to lead to a successful future.
Knee sales increased by 2 percent worldwide, extremity sales by 21 percent and sports medicine sales by 16 percent worldwide. The sales of spine products experienced a 3 percent decrease during the second quarter.
Read the release on Biomet's 2Q FY 2011 financial report.
Read other coverage on Biomet:
- Biomet Completes Enrollment for FDA Trial for PRP Device for Tennis Elbow Treatment
- Biomet Nederland, Small Bone Innovations Sign Distribution Agreement
- Biomet Acquires Massachusetts' Cytosol Laboratories